CONJUGATED LINOLEIC ACID SUPPLEMENTATION AS A TREATMENT IN TYPE 2 DIABETES MELLITUS; SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 389

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

INC15_581

تاریخ نمایه سازی: 30 دی 1397

چکیده مقاله:

Background and Aim: Numerous studies evidenced that conjugated linoleic acid (CLA) could effect on several diabetes related factors but finding was ControversialMethods: We searched the PubMed, Web of Science, Cochrane, Scopus and and the ClinicalTrials.gov up to January 2017. We used from a random-effects model to calculate the combined treatment effectsResults: Four studies which involved 116 participants were included in final analysis. CLA dose ranging from 3 to 6.4 mg/day. Compared with placebo, the pooled estimate of change was -1.28 (95% CI: -3.66, 1.10), 0.38 (95% CI: -0.26, 1.03), 0.00 (95% CI: -0.01, 0.01) and 0.03 (95% CI: -17.31, 17.26) for HOMA-IR, HbA1c, QUICKI and FBS Respectively. Conclusion: The finding of this study was not support for benfecial effect of CLA in diabetic patients.

نویسندگان

Loghman Sharifi

Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran

Hosein Rostami

Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Mehran Rahimlou

Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences,Ahvaz,Iran

Azadeh Dehghani Kari Bozorg

Department of Community Nutrition, School of Nutritional Sciences and Dietetics, international campus,Tehran University of Medical Sciences (TUMS), Tehran, Iran